🔗 Share this article

Given that America continues making sweeping changes to its vaccination recommendations, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who initially gained attention by expressing skepticism about Covid shots in the pandemic and has zeroed in on possible fatalities following COVID-19 vaccination in her short tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Schedule

Public health authorities had intended to announce radical revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s vaccine program, sources say – a major change that would put the US out of step with much of the world with insufficient data for improved outcomes. The planned update has been pushed back until the coming year.

Rather than the director of the vaccine center, Høeg is scheduled to address the audience at the meeting. She was newly appointed interim head of the FDA’s CDER, the fifth person to lead the office this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it signals a renewed priority upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US in order to be more like Denmark, a country with comprehensive healthcare and a population roughly the size of Wisconsin’s.

In her initial statements, she has continued to focus on vaccination policy – usually the domain of Dr. Prasad, director of the FDA’s vaccine center – instead of medication approval.

Concerns Over Qualifications

Høeg has little discernible background in pharmaceutical research, approval processes or management, which has been standard for former directors of the biologics center. She has worked at the FDA as a top consultant to the agency head and CBER since spring.

“She doesn’t seem to have the requisite experience” for running the drug-regulation department, said Jonathan Howard. “She has not conducted a scientific study. She is not versed in managing a large organization. She is not an expert in industry regulation.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the underlying principles of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that previous people who led CBER have had.”

CDER has an immense workload at the FDA, the former commissioner pointed out.

“Everybody just pays attention on the new drug program, but the generic program clears thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and so forth, and all of those need to be supervised,” she noted. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a substantial leadership component to the position, which manages over 5,000 personnel. “It is a enormous administrative position, if you do it right,” the former official added.

Official Statement and Contentious Policies

In response to inquiries about Høeg’s qualifications and whether this selection indicates greater collaboration among FDA leaders on immunizations, a press secretary said that the “concerns rely on incorrect premises”.

“Her experience matches the functions of her job,” the official said, noting the period Dr. Høeg spent advising the agency head on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s new expedited review system, a controversial rapid drug-approval program that reportedly concerned her preceding directors. “How are these medications being selected for this fast-track system? Who makes the choices?” Dr. Howard said. “There is a lot of secrecy occurring at the agency right now.”

Broadly speaking, he stated, “the Food and Drug Administration seems to be moving towards more relaxed oversight of most medications, with the exception of immunizations.”

Documented Track Record on Immunizations

With vaccines, Dr. Høeg has a clearer, if troubling, track record, critics said. She published a study using unconfirmed volunteer-provided data to estimate the incidence of heart inflammation after COVID-19 immunization. She counseled the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccinations are riskier than they are.

Among her “desired changes” for the new government included revising rules for recently developed shots and discontinuing “optional” immunizations, she stated post-election on a podcast. At the FDA, Dr. Høeg has according to sources suggested barring young men from getting Covid vaccines.

“She is an thorough dogmatist who begins with her conclusions and works backwards to retrofit the science in a very deceptive, dishonest fashion,” Dr. Howard stated.

Taking Control and a “Campaign of Retribution”

Høeg joined other dissenters, {like|